Abstract:BACKGROUND: Next generation sequencing for copy number variants is often used as a follow-up investigation of unusual fetal ultrasound results and is capable of detecting CNVs with a resolution of ∼0.1 Mb. In a prenatal setting, observation and subsequent management of pregnancies with a fetal variant of uncertain significance (VUS) remains problematic for counselling.OBJECTIVE: To follow the decision-making processes of pregnancies identified with a fetal VUS and prospectively assess CNV interpretations and implications under the newer 2020 American College of Medical Genetics and Genomics (ACMG) guidelines.STUDY DESIGN: In a single prenatal unit, prospective chromosome testing using copy number variation sequencing for 8030 fetuses with unexpected noninvasive findings identified 139 pregnancies with a CNV classified as a VUS according to the 2015 ACMG guidelines current at the time. Parent-of-origin testing was subsequently performed to determine if the CNV was inherited or de novo. All couples were offered specialized genetic counselling to assist in pregnancy management decisions. For the continued pregnancies that reached term, newborns were clinically assessed for evidence of any disease at 0-10 months and/or between 2-4 years of age.RESULTS: Of the 139 VUS found, most (78%) were inherited with no evidence of disease in the carrier parent. Based on primary ultrasound findings combined with results from non-invasive prenatal screening tests, most inherited VUS pregnancies were continued whereas most pregnancies involving de novo VUS were terminated. From clinical follow-up of the 113 livebirths, only 5 showed any evidence of a phenotype that was not apparently related to the original VUS. Prospective reanalysis of the 139 VUS using recent 2020 ACMG guidelines changed the status of 24 VUS with 15 reclassified as benign and 9 regraded to pathogenic. However, the 5 children born with an inherited VUS reclassified as pathogenic showed no evidence of a disease phenotype on clinical follow up.CONCLUSIONS: The severity of fetal ultrasound findings combined with results from parent-of-origin testing were the key drivers in pregnancy management decisions for patients. Based on birth outcomes from continued pregnancies, most VUS proved to be apparently benign in nature and potentially of low risk of an adverse disease outcome. There was a discordance rate of 17% for VUS scoring between the 2015 and 2020 ACMG guidelines for defining a VUS suggesting that difficulties remain for predicting true pathogenicity. Nonetheless, with increasing knowledge of population CNV polymorphisms, and a more complete assessment for alternative genetic causes, patients having prenatal assessments should feel less anxious when a fetal VUS is identified.

Assessing management practices for variants of uncertain significance among genetic counselors in pediatrics

Enhancing Variant of Uncertain Significance (VUS) Interpretation in Neurogenetics: Collaborative Experiences from a Tertiary Care Centre

Experiences of individuals with a variant of uncertain significance on genetic testing for hereditary cancer risks: a mixed method systematic review

Germline Variants of Uncertain Significance in Gynecologic Oncology Patients

The uncertainty of copy number variants: pregnancy decisions and clinical follow up

Reinterpretation of BRCA1 and BRCA2 variants of uncertain significance in patients with hereditary breast/ovarian cancer using the ACMG/AMP 2015 guidelines

Comparison of medical management and genetic counseling options pre- and post-whole exome sequencing for patients with positive and negative results.

Distinct rates of VUS reclassification are observed when subclassifying VUS by evidence level

The frequency of gene variant reclassification and its impact on clinical management in the inherited arrhythmia clinic

The recommendation of re-classification of variants of uncertain significance (VUS) in adult genetic disorders patients

Management of amended variant classification laboratory reports by genetic counselors in the United States and Canada: An exploratory study

Fragmented responsibility: views of Israeli HCPs regarding patient recontact following variant reclassification

The Development and Evaluation of Novel Patient Educational Material for a Variant of Uncertain Significance (VUS) Result in Hereditary Cancer Genes

Exploring the factors affecting classification and reporting of uncertain prenatal microarray findings, using a "virtual fetus" model‐a pilot study

Release of reclassified VUS results of now deceased patients to family members: Practices and opinions

What do cancer genetic providers want us to know about variant reclassification and recontact that we are not asking? A thematic analysis of open‐ended survey responses

Unrecognised actionability for breast cancer risk variants identified in a national-level review of Australian familial cancer centres

Clinical Utility of Molecular Tumor Board Review for Identification of Possible Germline Pathogenic Variants on Tumor Next-Generation Sequencing Reports

Current and Future Approaches to Classify VUSs in LGMD-Related Genes

Bioinformatics characterization of variants of uncertain significance in pediatric sensorineural hearing loss

Variant classification changes over time in the clinical molecular diagnostic laboratory setting